364 related articles for article (PubMed ID: 17804511)
1. B7 costimulation molecules expressed from the herpes simplex virus 2 genome rescue immune induction in B7-deficient mice.
Thebeau LG; Vagvala SP; Wong YM; Morrison LA
J Virol; 2007 Nov; 81(22):12200-9. PubMed ID: 17804511
[TBL] [Abstract][Full Text] [Related]
2. Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice.
Vagvala SP; Thebeau LG; Wilson SR; Morrison LA
J Virol; 2009 Jan; 83(2):953-60. PubMed ID: 18987142
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.
Morrison LA; Zhu L; Thebeau LG
J Virol; 2001 Feb; 75(3):1195-204. PubMed ID: 11152492
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
[TBL] [Abstract][Full Text] [Related]
5. ICP8-vhs- HSV-2 Vaccine Expressing B7 Costimulation Molecules Optimizes Safety and Efficacy against HSV-2 Infection in Mice.
Korom M; Wang H; Bernier KM; Geiss BJ; Morrison LA
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515256
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of reduced T-cell effector functions and class-switched antibody responses to herpes simplex virus type 2 in the absence of B7 costimulation.
Thebeau LG; Morrison LA
J Virol; 2003 Feb; 77(4):2426-35. PubMed ID: 12551980
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
[TBL] [Abstract][Full Text] [Related]
8. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease.
Da Costa XJ; Bourne N; Stanberry LR; Knipe DM
Virology; 1997 May; 232(1):1-12. PubMed ID: 9185583
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with a HSV-2 UL24 mutant induces a protective immune response in murine and guinea pig vaginal infection models.
Visalli RJ; Natuk RJ; Kowalski J; Guo M; Blakeney S; Gangolli S; Cooper D
Vaccine; 2014 Mar; 32(12):1398-406. PubMed ID: 24462481
[TBL] [Abstract][Full Text] [Related]
11. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.
Brans R; Yao F
BMC Microbiol; 2010 Jun; 10():163. PubMed ID: 20525279
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
[TBL] [Abstract][Full Text] [Related]
13. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
Tengvall S; O'Hagan D; Harandi AM
Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.
Görander S; Harandi AM; Lindqvist M; Bergström T; Liljeqvist JÅ
J Virol; 2012 Jul; 86(14):7544-53. PubMed ID: 22553328
[TBL] [Abstract][Full Text] [Related]
16. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
Bettahi I; Zhang X; Afifi RE; BenMohamed L
Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
[TBL] [Abstract][Full Text] [Related]
17. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
18. Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells.
Brockman MA; Verschoor A; Zhu J; Carroll MC; Knipe DM
J Virol; 2006 Jul; 80(14):7111-7. PubMed ID: 16809316
[TBL] [Abstract][Full Text] [Related]
19. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
Osorio Y; Ghiasi H
J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
[TBL] [Abstract][Full Text] [Related]
20. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
Awasthi S; Huang J; Shaw C; Friedman HM
J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
